Efficacy, Immunogenicity and Safty Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)
Conditions: Cervical Intraepithelial Neoplasia; Cervical Cancer; Condylomata Acuminata Interventions: Biological: Nonavalent HPV vaccine; Biological: Bivalent HPV vaccine Sponsors: Xiamen University; Xiamen Innovax Biotech Co., Ltd; Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Biotechnology | Cancer | Cancer & Oncology | Cancer Vaccines | Cervical Cancer Vaccine | Gardasil | Gastroenteritis | Genital Warts | Human Papillomavirus (HPV) | Research | Study | Vaccines